These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 8959623)
1. Inhibition of progression of chronic puromycin aminonucleoside nephrosis by probucol, an antioxidant. Magil A J Am Soc Nephrol; 1996 Nov; 7(11):2340-7. PubMed ID: 8959623 [TBL] [Abstract][Full Text] [Related]
2. Failure of antioxidant therapy to attenuate interstitial disease in rats with reversible nephrotic syndrome. Drukker A; Eddy AA J Am Soc Nephrol; 1998 Feb; 9(2):243-51. PubMed ID: 9527400 [TBL] [Abstract][Full Text] [Related]
3. Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. Lee HS; Jeong JY; Kim BC; Kim YS; Zhang YZ; Chung HK Kidney Int; 1997 Apr; 51(4):1151-9. PubMed ID: 9083281 [TBL] [Abstract][Full Text] [Related]
4. Osteopontin in chronic puromycin aminonucleoside nephrosis. Magil AB; Pichler RH; Johnson RJ J Am Soc Nephrol; 1997 Sep; 8(9):1383-90. PubMed ID: 9294829 [TBL] [Abstract][Full Text] [Related]
5. Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis. Hirano T; Morohoshi T Nephron; 1992; 60(4):443-7. PubMed ID: 1584321 [TBL] [Abstract][Full Text] [Related]
6. Antioxidants protect podocyte foot processes in puromycin aminonucleoside-treated rats. Ricardo SD; Bertram JF; Ryan GB J Am Soc Nephrol; 1994 Jun; 4(12):1974-86. PubMed ID: 7919151 [TBL] [Abstract][Full Text] [Related]